Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Emergent Biosolutions Inc (NYSE: EBS) closed at $12.85 in the last session, up 2.72% from day before closing price of $12.51. In other words, the price has increased by $2.72 from its previous closing price. On the day, 0.93 million shares were traded. EBS stock price reached its highest trading level at $12.95 during the session, while it also had its lowest trading level at $12.355.
Ratios:
We take a closer look at EBS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 482.05. For the most recent quarter (mrq), Quick Ratio is recorded 3.15 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 22 ’25 when LOUIS W SULLIVAN bought 104,695 shares for $12.77 per share.
Richard Ronald sold 21,984 shares of EBS for $263,077 on Dec 05 ’25. The Director now owns 98,417 shares after completing the transaction at $11.97 per share. On Dec 05 ’25, another insider, RONALD RICHARD, who serves as the Director of the company, bought 32,848 shares for $11.94 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 685561664 and an Enterprise Value of 1100381568. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.86 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 1.395 whereas that against EBITDA is 5.002.
Stock Price History:
The Beta on a monthly basis for EBS is 2.35, which has changed by 0.2169261 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.41, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 14.67%, while the 200-Day Moving Average is calculated to be 60.02%.
Shares Statistics:
According to the various share statistics, EBS traded on average about 1.03M shares per day over the past 3-months and 751360 shares per day over the past 10 days. A total of 52.70M shares are outstanding, with a floating share count of 50.42M. Insiders hold about 3.99% of the company’s shares, while institutions hold 79.62% stake in the company. Shares short for EBS as of 1765756800 were 9020934 with a Short Ratio of 8.74, compared to 1763078400 on 9260505. Therefore, it implies a Short% of Shares Outstanding of 9020934 and a Short% of Float of 17.36.
Earnings Estimates
. The current rating of Emergent Biosolutions Inc (EBS) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.97, with high estimates of $0.97 and low estimates of $0.97.
Analysts are recommending an EPS of between $2.05 and $2.05 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $4.02, with 1.0 analysts recommending between $4.02 and $4.02.
Revenue Estimates
According to 2 analysts,. The current quarter’s revenue is expected to be $217.5M. It ranges from a high estimate of $220M to a low estimate of $215M. As of. The current estimate, Emergent Biosolutions Inc’s year-ago sales were $194.7MFor the next quarter, 2 analysts are estimating revenue of $275M. There is a high estimate of $275M for the next quarter, whereas the lowest estimate is $275M.
A total of 2 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $809.6M, while the lowest revenue estimate was $809.2M, resulting in an average revenue estimate of $809.4M. In the same quarter a year ago, actual revenue was $1.04BBased on 1 analysts’ estimates, the company’s revenue will be $1.16B in the next fiscal year. The high estimate is $1.16B and the low estimate is $1.16B.
